BTIG analyst Thomas Shrader downgraded Athira Pharma (NASDAQ: ATHA) from Buy to Neutral.The analyst comments: "We don't see Fosgo with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE